Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Antiproliferative and antiosteoclastic activity from preclinical models show potential for dasatinib, an oral SRC and SRC family kinase inhibitor, as a targeted therapy for patients with prostate cancer. This phase II study investigated the activity of dasatinib in patients with metastatic...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yu, Evan Y., Wilding, George, Posadas, Edwin, Gross, Mitchell, Culine, Stephane, Massard, Christophe, Morris, Michael J., Hudes, Gary, Calabrò, Fabio, Cheng, Shinta, Trudel, Géralyn C., Paliwal, Prashni, Sternberg, Cora N.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394097/
https://ncbi.nlm.nih.gov/pubmed/19920114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1691
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky